Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giuseppe Procopio

Showing results (111-120 of 289) with videos related to

Pageof 29
Sort By:
Tumori|August 18, 2021
Update on radioligand therapy with <sup>177</sup>Lu-PSMA for metastatic castration-resistant prostate cancer: clinical aspects and survival effectsValentina Fuoco, Giovanni Argiroffi, Stefania Mazzaglia, et al.
Tumori|March 3, 2020
Safety and activity of radium-223 in metastatic castration-resistant prostate cancer: the experience of Istituto Nazionale dei TumoriAlessandra Raimondi, Pierangela Sepe, Melanie Claps, et al.
Current Oncology Reports|March 31, 2023
Current Status of Predictive Biomarker Development in Metastatic Renal Cell CarcinomaGiuseppe Fotia, Marco Stellato, Valentina Guadalupi, et al.
JAMA Oncology|April 14, 2022
Cabozantinib as First-line Treatment in Patients With Metastatic Collecting Duct Renal Cell Carcinoma: Results of the BONSAI Trial for the Italian Network for Research in Urologic-Oncology (Meet-URO 2 Study)Giuseppe Procopio, Pierangela Sepe, Melanie Claps, et al.
Future Oncology (London, England)|August 23, 2014
Safety profile and treatment response of everolimus in different solid tumors: an observational studyElena Verzoni, Sara Pusceddu, Roberto Buzzoni, et al.
Japanese Journal of Clinical Oncology|November 19, 2020
An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic renal-cell carcinoma patients: the 'Pamerit' studyAlessandra Mosca, Ugo De Giorgi, Giuseppe Procopio, et al.
International Journal of Molecular Sciences|February 27, 2020
Analysis of Single Circulating Tumor Cells in Renal Cell Carcinoma Reveals Phenotypic Heterogeneity and Genomic Alterations Related to ProgressionVera Cappelletti, Elena Verzoni, Raffaele Ratta, et al.
Journal of Translational Medicine|August 4, 2021
Clinical outcome of renal cancer patients who early interrupted immunotherapy due to serious immune-related adverse events. Meet-Uro 13 trial on behalf of the MeetUro investigatorsMarco Stellato, Giuseppe Procopio, Ugo De Giorgi, et al.
Journal of Clinical Medicine|April 2, 2020
Angiogenesis and Immunity in Renal Carcinoma: Can We Turn an Unhappy Relationship into a Happy Marriage?Alessia Mennitto, Veronica Huber, Raffaele Ratta, et al.
Cancer Treatment Reviews|November 19, 2023
Vascular endothelial growth factor-targeted therapy in patients with renal cell carcinoma pretreated with immune checkpoint inhibitors: A systematic literature reviewLaurence Albiges, Bradley A McGregor, Daniel Y C Heng, et al.
Pageof 29

Showing results (111-120 of 289) with videos related to

Sort By:
Pageof 29
Tumori|August 18, 2021
Update on radioligand therapy with <sup>177</sup>Lu-PSMA for metastatic castration-resistant prostate cancer: clinical aspects and survival effectsValentina Fuoco, Giovanni Argiroffi, Stefania Mazzaglia, et al.
Tumori|March 3, 2020
Safety and activity of radium-223 in metastatic castration-resistant prostate cancer: the experience of Istituto Nazionale dei TumoriAlessandra Raimondi, Pierangela Sepe, Melanie Claps, et al.
Current Oncology Reports|March 31, 2023
Current Status of Predictive Biomarker Development in Metastatic Renal Cell CarcinomaGiuseppe Fotia, Marco Stellato, Valentina Guadalupi, et al.
JAMA Oncology|April 14, 2022
Cabozantinib as First-line Treatment in Patients With Metastatic Collecting Duct Renal Cell Carcinoma: Results of the BONSAI Trial for the Italian Network for Research in Urologic-Oncology (Meet-URO 2 Study)Giuseppe Procopio, Pierangela Sepe, Melanie Claps, et al.
Future Oncology (London, England)|August 23, 2014
Safety profile and treatment response of everolimus in different solid tumors: an observational studyElena Verzoni, Sara Pusceddu, Roberto Buzzoni, et al.
Japanese Journal of Clinical Oncology|November 19, 2020
An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic renal-cell carcinoma patients: the 'Pamerit' studyAlessandra Mosca, Ugo De Giorgi, Giuseppe Procopio, et al.
International Journal of Molecular Sciences|February 27, 2020
Analysis of Single Circulating Tumor Cells in Renal Cell Carcinoma Reveals Phenotypic Heterogeneity and Genomic Alterations Related to ProgressionVera Cappelletti, Elena Verzoni, Raffaele Ratta, et al.
Journal of Translational Medicine|August 4, 2021
Clinical outcome of renal cancer patients who early interrupted immunotherapy due to serious immune-related adverse events. Meet-Uro 13 trial on behalf of the MeetUro investigatorsMarco Stellato, Giuseppe Procopio, Ugo De Giorgi, et al.
Journal of Clinical Medicine|April 2, 2020
Angiogenesis and Immunity in Renal Carcinoma: Can We Turn an Unhappy Relationship into a Happy Marriage?Alessia Mennitto, Veronica Huber, Raffaele Ratta, et al.
Cancer Treatment Reviews|November 19, 2023
Vascular endothelial growth factor-targeted therapy in patients with renal cell carcinoma pretreated with immune checkpoint inhibitors: A systematic literature reviewLaurence Albiges, Bradley A McGregor, Daniel Y C Heng, et al.
Pageof 29